Auxilium Health raises oversubscribed $3.4 million seed round to advance Aer biomaterial platform. July 14, 2026 Auxilium Health has closed an oversubscribed $3.4 million seed financing, approximately one year after its pre-seed round, to accelerate development of its Aer(TM) biomaterial platform toward FDA clearance and first-in-human clinical studies. The financing was backed by both existing and new regional and strategic investors, more than doubling the company's previous funding and supporting continued expansion of its research and development efforts. Auxilium is developing a new class of bioaerogels designed to address one of the longstanding challenges in biomaterials: preventing bacterial colonization while promoting tissue regeneration. Rather than relying on antibiotics, the company's Aer(TM) platform is engineered to mimic the body's extracellular matrix, resisting bacterial attachment while encouraging regenerative cells to populate the material. The new capital will fund advancement of the company's lead product through regulatory development, expand its scientific team, and support additional research. Over the past year, Auxilium said it has doubled its full-time workforce, recruiting researchers and scientists to its Cleveland headquarters. "Last year, the question was whether the science was real. This year, it's how fast we can get it to patients," said Isaiah Kaiser, PhD, Founder and CEO of Auxilium Health. "We're grateful to our investors and partners who believe in the science and the team behind what we're building." Headquartered at the Cleveland Clinic's Global Innovation Center, Auxilium Health develops biomaterials for wound repair, bone regeneration, and localized therapeutic delivery. The company is also supported by the National Science Foundation, the Ohio Department of Development, and the Polymer Industry Cluster.

Auxilium Health closes oversubscribed $3.4 million seed round to advance its Aer(TM) biomaterial platform. Science · JUL 14, 2026 PR Newswire CLEVELAND, July 14, 2026 /PRNewswire/ - Auxilium Health today announced the close of an oversubscribed $3.4 million seed round, a year after closing its... CLEVELAND, July 14, 2026 /PRNewswire/ - Auxilium Health today announced the close of an oversubscribed $3.4 million seed round, a year after closing its pre-seed, to advance its Aer(TM) biomaterial platform toward FDA clearance and first-in-human studies. Backed by returning and new regional and strategic investors, the round more than doubles the company's prior raise and reflects growing conviction in both the technology and the progress behind it. For nearly four decades, biomaterials have tried to win what surgeons and scientists call the "race for the surface," the contest between a patient's healing cells and bacteria to colonize a material first, by killing bacteria after they arrive. Auxilium takes a different approach. Its Aer(TM) platform is an engineered matrix-like product that mimics the body's own extracellular matrix, built to win that race structurally by resisting bacterial attachment while welcoming regenerative cells, all without relying on antibiotics. The new capital will advance the company's lead product toward FDA clearance and into first-in-human use while deepening the team and the research behind it. Over the last year, Auxilium's full-time team has doubled, attracting top researchers and scientists to relocate to Cleveland to join the mission. "Last year, the question was whether the science was real. This year, it's how fast we can get it to patients," said Isaiah Kaiser, PhD, Founder and CEO of Auxilium Health. "We're grateful to our investors and partners who believe in the science and the team behind what we're building. Their confidence lets us move with the urgency this problem deserves." About Auxilium Health Auxilium Health develops a new class of bioaerogels that reduce the risk of bacterial colonization and guide tissue regeneration. Its Aer(TM) platform spans wound repair, bone regeneration, and localized delivery, with a lead product advancing toward FDA clearance and clinical studies. Headquartered at the Cleveland Clinic's Global Innovation Center, the company is supported by the National Science Foundation, the Ohio Department of Development, and the Polymer Industry Cluster. Regeneration begins at the surface. Media Contact Lindsey Dinneen Director of Marketing & Engagement Project Medtech [email protected] SOURCE Auxilium Health Published by News Desk · WeeklyReviewer The WeeklyReviewer news desk monitors breaking developments around the clock - sourcing, verifying, and publishing real-time industry news across business, technology, politics, science, sports, and world affairs. Every story that comes through the Live Wire is reviewed for accuracy before publication, keeping our readers ahead of the curve without the noise.